Open Access

Science

, volume 375 , issue 6576 , pages 43-50

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Peter G. Gilbert ^{1, 2, 3}

David C. Montefiori ⁴

Adrian B. McDermott ⁵

Youyi Fong ^{1, 2}

David Benkeser ⁶

Weiping Deng ⁷

Honghong Zhou ⁷

Christopher R Houchens ⁸

Karen J.B. Martins ⁸

Lakshmi Jayashankar ⁸

Flora Castellino ⁸

Britta Flach ⁵

Bob C Lin ⁵

Sarah O’Connell ⁵

Charlene McDanal ⁴

Amanda J. Eaton ⁴

Marcella Sarzotti-Kelsoe ⁴

Yiwen Lu ¹

Chenchen Yu ¹

Bhavesh Borate ¹

Lars W. P. van der Laan ¹

Nima S. Hejazi ^{1, 9}

Huynh Chuong ⁸

Jacqueline Miller ⁷

Hana M El Sahly ¹⁰

Lindsey R. Baden ¹¹

Mira Baron ¹²

Luis de la Cruz ¹³

Cynthia Gay ¹⁴

Spyros Kalams ¹⁵

Colleen F. Kelley ¹⁶

Michele P Andrasik ¹

James G Kublin ¹

Lawrence Corey ^{1, 17}

Kathleen M. Neuzil ¹⁸

Lindsay N. Carpp ¹

Rolando Pajon ⁷

Dean Follmann ¹⁹

Ruben O Donis ⁸

Richard A. Koup ⁵

Hide authors affiliations Show authors affiliations: 19 affiliations

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. |

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. |

Department of Biostatistics, University of Washington, Seattle, WA, USA. |

⁴

Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA. |

⁵

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. |

⁶

Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA. |

⁷

Moderna, Inc., Cambridge, MA, USA. |

⁸

Biomedical Advanced Research and Development Authority, Washington, DC, USA. |

⁹

Division of Biostatistics, School of Public Health, University of California Berkeley, Berkeley, CA, USA. |

¹⁰

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. |

¹¹

Brigham and Women’s Hospital, Boston, MA, USA. |

¹²

Palm Beach Research Center, West Palm Beach, FL, USA. |

¹³

Keystone Vitalink Research, Greenville, SC, USA. |

¹⁴

Department of Medicine, Division of Infectious Diseases, UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. |

¹⁵

Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. |

¹⁶

Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine and the Grady Health System, Atlanta, GA, USA. |

¹⁷

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. |

¹⁸

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. |

¹⁹

Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. |

Publication type: Journal Article

Publication date: 2022-01-07

American Association for the Advancement of Science (AAAS)

Science

scimago Q1

wos Q1

SJR: 10.416

CiteScore: 48.4

Impact factor: 45.8

ISSN: 00368075, 10959203

DOI: 10.1126/science.abm3425

Copy DOI

PubMed ID: 34812653

Multidisciplinary

Abstract

Antibody levels predict vaccine efficacy

Symptomatic COVID-19 infection can be prevented by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. A “correlate of protection” is a molecular biomarker to measure how much immunity is needed to fight infection and is key for successful global immunization programs. Gilbert et al . determined that antibodies are the correlate of protection in vaccinated individuals enrolled in the Moderna COVE phase 3 clinical trial (see the Perspective by Openshaw). By measuring binding and neutralizing antibodies against the viral spike protein, the authors found that the levels of both antibodies correlated with the degree of vaccine efficacy. The higher the antibody level, the greater the protection afforded by the messenger RNA (mRNA) vaccine. Antibody levels that predict mRNA vaccine efficacy can therefore be used to guide vaccine regimen modifications and support regulatory approvals for a broader spectrum of the population. —PNK

Found

1 citation

Vakhrusheva Anna

🤝

PhD in Biological/biomedical sciences

18 publications, 265 citations

h-index: 7

Lomonosov Moscow State University

Research interests

Bioengineering

1 citation

Dolzhikova Inna

🥼

PhD in Biological/biomedical sciences

54 publications, 2 910 citations

h-index: 15

N. F. Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation

D. I. Ivanovsky Institute of Virology

RNA drugs and vaccines

Virology

1 citation

Belenkaya Svetlana

PhD in Biological/biomedical sciences

39 publications, 263 citations

h-index: 9

State Research Center of Virology and Biotechnology VECTOR

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences

1 citation

Nesmeyanova Valentina

18 publications, 123 citations

h-index: 6

State Research Center of Virology and Biotechnology VECTOR

Research interests

Biotechnology

Genetic engineering

1 citation

Takefuji Yoshiyasu

239 publications, 386 citations, 39 reviews

Artificial intelligence

Data Science

IOT

1 citation

Alexandrino Eduardo

59 publications, 1 516 citations

h-index: 15

Federal University of São Paulo

Research interests

Antimicrobial resistance

COVID-19

Top-30

Journals

	5 10 15 20 25 30 35 40 45
Vaccines	Vaccines, 45, 4.78% Vaccines 45 publications, 4.78%
Nature Communications	Nature Communications, 37, 3.93% Nature Communications 37 publications, 3.93%
Vaccine	Vaccine, 37, 3.93% Vaccine 37 publications, 3.93%
Frontiers in Immunology	Frontiers in Immunology, 36, 3.83% Frontiers in Immunology 36 publications, 3.83%
Journal of Infectious Diseases	Journal of Infectious Diseases, 21, 2.23% Journal of Infectious Diseases 21 publications, 2.23%
medRxiv : the preprint server for health sciences	medRxiv : the preprint server for health sciences, 20, 2.13% medRxiv : the preprint server for health sciences 20 publications, 2.13%
npj Vaccines	npj Vaccines, 18, 1.91% npj Vaccines 18 publications, 1.91%
bioRxiv	bioRxiv, 17, 1.81% bioRxiv 17 publications, 1.81%
Clinical Infectious Diseases	Clinical Infectious Diseases, 16, 1.7% Clinical Infectious Diseases 16 publications, 1.7%
Scientific Reports	Scientific Reports, 16, 1.7% Scientific Reports 16 publications, 1.7%
Journal of Medical Virology	Journal of Medical Virology, 14, 1.49% Journal of Medical Virology 14 publications, 1.49%
Viruses	Viruses, 13, 1.38% Viruses 13 publications, 1.38%
Nature Medicine	Nature Medicine, 13, 1.38% Nature Medicine 13 publications, 1.38%
iScience	iScience, 13, 1.38% iScience 13 publications, 1.38%
EBioMedicine	EBioMedicine, 12, 1.28% EBioMedicine 12 publications, 1.28%
Open Forum Infectious Diseases	Open Forum Infectious Diseases, 12, 1.28% Open Forum Infectious Diseases 12 publications, 1.28%
Cell Reports Medicine	Cell Reports Medicine, 11, 1.17% Cell Reports Medicine 11 publications, 1.17%
Cell	Cell, 11, 1.17% Cell 11 publications, 1.17%
Human Vaccines and Immunotherapeutics	Human Vaccines and Immunotherapeutics, 11, 1.17% Human Vaccines and Immunotherapeutics 11 publications, 1.17%
Science Translational Medicine	Science Translational Medicine, 10, 1.06% Science Translational Medicine 10 publications, 1.06%
PLoS ONE	PLoS ONE, 9, 0.96% PLoS ONE 9 publications, 0.96%
Microbiology spectrum	Microbiology spectrum, 9, 0.96% Microbiology spectrum 9 publications, 0.96%
Nature Immunology	Nature Immunology, 7, 0.74% Nature Immunology 7 publications, 0.74%
Communications Medicine	Communications Medicine, 7, 0.74% Communications Medicine 7 publications, 0.74%
Cell Reports	Cell Reports, 7, 0.74% Cell Reports 7 publications, 0.74%
New England Journal of Medicine	New England Journal of Medicine, 6, 0.64% New England Journal of Medicine 6 publications, 0.64%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 6, 0.64% International Journal of Molecular Sciences 6 publications, 0.64%
EClinicalMedicine	EClinicalMedicine, 6, 0.64% EClinicalMedicine 6 publications, 0.64%
Emerging Microbes & Infections	Emerging Microbes & Infections, 6, 0.64% Emerging Microbes & Infections 6 publications, 0.64%
	5 10 15 20 25 30 35 40 45

Publishers

	50 100 150 200 250
Elsevier	Elsevier, 207, 22% Elsevier 207 publications, 22%
Springer Nature	Springer Nature, 161, 17.11% Springer Nature 161 publications, 17.11%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 128, 13.6% Cold Spring Harbor Laboratory 128 publications, 13.6%
MDPI	MDPI, 85, 9.03% MDPI 85 publications, 9.03%
Wiley	Wiley, 63, 6.7% Wiley 63 publications, 6.7%
Oxford University Press	Oxford University Press, 60, 6.38% Oxford University Press 60 publications, 6.38%
Frontiers Media S.A.	Frontiers Media S.A., 47, 4.99% Frontiers Media S.A. 47 publications, 4.99%
Taylor & Francis	Taylor & Francis, 22, 2.34% Taylor & Francis 22 publications, 2.34%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 21, 2.23% American Association for the Advancement of Science (AAAS) 21 publications, 2.23%
American Society for Microbiology	American Society for Microbiology, 19, 2.02% American Society for Microbiology 19 publications, 2.02%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 16, 1.7% Public Library of Science (PLoS) 16 publications, 1.7%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 15, 1.59% Ovid Technologies (Wolters Kluwer Health) 15 publications, 1.59%
BMJ	BMJ, 10, 1.06% BMJ 10 publications, 1.06%
Massachusetts Medical Society	Massachusetts Medical Society, 6, 0.64% Massachusetts Medical Society 6 publications, 0.64%
American Medical Association (AMA)	American Medical Association (AMA), 4, 0.43% American Medical Association (AMA) 4 publications, 0.43%
American Society for Clinical Investigation	American Society for Clinical Investigation, 4, 0.43% American Society for Clinical Investigation 4 publications, 0.43%
American College of Physicians	American College of Physicians, 3, 0.32% American College of Physicians 3 publications, 0.32%
Centers for Disease Control and Prevention (CDC)	Centers for Disease Control and Prevention (CDC), 3, 0.32% Centers for Disease Control and Prevention (CDC) 3 publications, 0.32%
SAGE	SAGE, 3, 0.32% SAGE 3 publications, 0.32%
eLife Sciences Publications	eLife Sciences Publications, 3, 0.32% eLife Sciences Publications 3 publications, 0.32%
Research Square Platform LLC	Research Square Platform LLC, 3, 0.32% Research Square Platform LLC 3 publications, 0.32%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 2, 0.21% Georg Thieme Verlag KG 2 publications, 0.21%
Annual Reviews	Annual Reviews, 2, 0.21% Annual Reviews 2 publications, 0.21%
Walter de Gruyter	Walter de Gruyter, 2, 0.21% Walter de Gruyter 2 publications, 0.21%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 2, 0.21% American Association for Cancer Research (AACR) 2 publications, 0.21%
American Academy of Pediatrics	American Academy of Pediatrics, 2, 0.21% American Academy of Pediatrics 2 publications, 0.21%
The American Association of Immunologists	The American Association of Immunologists, 2, 0.21% The American Association of Immunologists 2 publications, 0.21%
Institute of Electrical and Electronics Engineers (IEEE)	Institute of Electrical and Electronics Engineers (IEEE), 2, 0.21% Institute of Electrical and Electronics Engineers (IEEE) 2 publications, 0.21%
	50 100 150 200 250

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

944

Cite this

GOST |

Cite this

GOST Copy

Gilbert P. G. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial // Science. 2022. Vol. 375. No. 6576. pp. 43-50.

GOST all authors (up to 50) Copy

Gilbert P. G., Montefiori D. C., McDermott A. B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C. R., Martins K. J., Jayashankar L., Castellino F., Flach B., Lin B. C., O’Connell S., McDanal C., Eaton A. J., Sarzotti-Kelsoe M., Lu Y., Yu C., Borate B., van der Laan L. W. P., Hejazi N. S., Chuong H., Miller J., El Sahly H. M., Baden L. R., Baron M., de la Cruz L., Gay C., Kalams S., Kelley C. F., Andrasik M. P., Kublin J. G., Corey L., Neuzil K. M., Carpp L. N., Pajon R., Follmann D., Donis R. O., Koup R. A. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial // Science. 2022. Vol. 375. No. 6576. pp. 43-50.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1126/science.abm3425

UR - https://doi.org/10.1126/science.abm3425

TI - Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

T2 - Science

AU - Gilbert, Peter G.

AU - Montefiori, David C.

AU - McDermott, Adrian B.

AU - Fong, Youyi

AU - Benkeser, David

AU - Deng, Weiping

AU - Zhou, Honghong

AU - Houchens, Christopher R

AU - Martins, Karen J.B.

AU - Jayashankar, Lakshmi

AU - Castellino, Flora

AU - Flach, Britta

AU - Lin, Bob C

AU - O’Connell, Sarah

AU - McDanal, Charlene

AU - Eaton, Amanda J.

AU - Sarzotti-Kelsoe, Marcella

AU - Lu, Yiwen

AU - Yu, Chenchen

AU - Borate, Bhavesh

AU - van der Laan, Lars W. P.

AU - Hejazi, Nima S.

AU - Chuong, Huynh

AU - Miller, Jacqueline

AU - El Sahly, Hana M

AU - Baden, Lindsey R.

AU - Baron, Mira

AU - de la Cruz, Luis

AU - Gay, Cynthia

AU - Kalams, Spyros

AU - Kelley, Colleen F.

AU - Andrasik, Michele P

AU - Kublin, James G

AU - Corey, Lawrence

AU - Neuzil, Kathleen M.

AU - Carpp, Lindsay N.

AU - Pajon, Rolando

AU - Follmann, Dean

AU - Donis, Ruben O

AU - Koup, Richard A.

PY - 2022

DA - 2022/01/07

PB - American Association for the Advancement of Science (AAAS)

SP - 43-50

IS - 6576

VL - 375

PMID - 34812653

SN - 0036-8075

SN - 1095-9203

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2022_Gilbert,

author = {Peter G. Gilbert and David C. Montefiori and Adrian B. McDermott and Youyi Fong and David Benkeser and Weiping Deng and Honghong Zhou and Christopher R Houchens and Karen J.B. Martins and Lakshmi Jayashankar and Flora Castellino and Britta Flach and Bob C Lin and Sarah O’Connell and Charlene McDanal and Amanda J. Eaton and Marcella Sarzotti-Kelsoe and Yiwen Lu and Chenchen Yu and Bhavesh Borate and Lars W. P. van der Laan and Nima S. Hejazi and Huynh Chuong and Jacqueline Miller and Hana M El Sahly and Lindsey R. Baden and Mira Baron and Luis de la Cruz and Cynthia Gay and Spyros Kalams and Colleen F. Kelley and Michele P Andrasik and James G Kublin and Lawrence Corey and Kathleen M. Neuzil and Lindsay N. Carpp and Rolando Pajon and Dean Follmann and Ruben O Donis and Richard A. Koup},

title = {Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial},

journal = {Science},

year = {2022},

volume = {375},

publisher = {American Association for the Advancement of Science (AAAS)},

month = {jan},

url = {https://doi.org/10.1126/science.abm3425},

number = {6576},

pages = {43--50},

doi = {10.1126/science.abm3425}

}

MLA

Cite this

MLA Copy

Gilbert, Peter G., et al. “Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.” Science, vol. 375, no. 6576, Jan. 2022, pp. 43-50. https://doi.org/10.1126/science.abm3425.

Publisher

American Association for the Advancement of Science (AAAS)

Journal

Science

scimago Q1

wos Q1

SJR

10.416

CiteScore

48.4

Impact factor

45.8

ISSN

00368075 (Print)

10959203 (Electronic)

Profiles